Stay updated on Nintedanib for Progressive Fibrosing ILD Clinical Trial
Sign up to get notified when there's something new on the Nintedanib for Progressive Fibrosing ILD Clinical Trial page.

Latest updates to the Nintedanib for Progressive Fibrosing ILD Clinical Trial page
- Check2 days agoChange DetectedThe webpage has removed detailed information about a clinical study on the efficacy and safety of nintedanib for treating Progressive Fibrosing Interstitial Lung Disease (PF-ILD), including the study's aim, inclusion and exclusion criteria, and other specifics. Additionally, it has added a reference to lung diseases and an EudraCT number.SummaryDifference18%
- Check9 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check16 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check23 days agoNo Change Detected
- Check52 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
- Check66 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.5%
- Check73 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.0%
Stay in the know with updates to Nintedanib for Progressive Fibrosing ILD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nintedanib for Progressive Fibrosing ILD Clinical Trial page.